STAT+: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug
In a surprise move, the FDA has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved.
In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.
The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.
A date for the meeting has not been set yet.
What's Your Reaction?
